Grey Wolf raises $50 million in Series B extension


United Kingdom

Grey Wolf Therapeutics Ltd, a UK company with a subsidiary in Australia, has raised $50 million in a Series B round extension to support development of a candidate drug for solid tumours. The drug, GRWD5769, is a small molecule inhibitor of an enzyme in the endoplasmic reticulum that plays a key role in the presentation of antigen to the human immune system. Initial data from an ongoing Phase 1/2 trial will be presented at the annual meeting of ASCO which takes place from 31 March to 4 June.